Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. by Roe, M.T. (Matthew) et al.
Clinical research
Creatine kinase-MB elevation after percutaneous
coronary intervention predicts adverse outcomes in
patients with acute coronary syndromes
M.T. Roea*, K.W. Mahaffeya, R. Kilarua, J.H. Alexandera, K.M. Akkerhuisb,
M.L. Simoonsb, R.A. Harringtona, B.E. Tardiffa, C.B. Grangera,
E.M. Ohmana, D.J. Moliternof, A.M. Lincoffc, P.W. Armstrongd,
F. Van de Werfe, R.M. Califfa, E.J. Topolc
aDuke Clinical Research Institute, Durham, North Carolina, USA
bUniversity Hospital, Rotterdam, The Netherlands
cCleveland Clinic Foundation, Cleveland, Ohio, USA
dUniversity of Alberta, Edmonton, Canada
eCatholic University Hospital, Leuven, Belgium
fUniversity of Kentucky, Lexington, Kentucky, USA
Received 20 February 2003; received in revised form 9 October 2003; accepted 4 December 2003
This paper was guest edited by Prof. Bernard J. Gersh, Mayo Clinic
Aim To study the relationship between outcomes and peak creatine kinase (CK)-MB
levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment
elevation acute coronary syndromes (NSTE ACS).
Methods and results Peak CK-MB ratios (peak CK-MB level/upper limit of normal
[ULN]) after PCI were analysed in 6164 patients with NSTE ACS from four randomized
trials who underwent in-hospital PCI. We excluded 696 patients with elevated CK or
CK-MB levels <24 h before PCI; the primary analysis included 2384 of the remaining
5468 patients (43.6%) with CK-MB levels measured ≤24 h after PCI. The incidence of
in-hospital heart failure (0.1%, 0.8%, 3.4%, 4.1%, and 6.1%; P<0.001), arrhythmias
(0.8%, 1.9%, 6.9%, 4.1%, and 7.9%; P<0.001), cardiogenic shock (0.1%, 1.3%, 2.0%,
2.3%, and 2.6%; P=0.004), and mortality through 6 months (2.1%, 2.4%, 4.9%, 4.1%, and
5.7%, P=0.005) was increased with peak CK-MB ratios of 0–1, 1–3, 3–5, 5–10, and
>10×ULN, respectively. The continuous peak CK-MB ratio after PCI significantly
predicted adjusted 6-month mortality (risk ratio, 1.06 per unit increase above ULN;
95% confidence interval, 1.01–1.11; P=0.017).
Conclusions Greater CK-MB elevation after PCI is independently associated with
adverse outcomes in NSTE ACS. These results underscore the adverse implications of
elevated CK-MB levels after PCI in this high-risk population.
© 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
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Introduction
Elevated cardiac enzyme levels can be detected in 10–
20% of patients undergoing percutaneous coronary inter-
vention (PCI), but the clinical significance of myocardial
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necrosis after PCI and the definition of periprocedural
myocardial infarction (MI) remain controversial.1–3 Mul-
tiple studies have shown an increased risk of mortality
with elevated levels of creatine kinase (CK) and CK-MB
isoenzymes after PCI.4–7 Although patients with acute
coronary syndromes (ACS) have a higher risk of pro-
cedural complications during PCI than patients under-
going elective coronary intervention, the incidence,
definition, and prognostic implications of periprocedural
cardiac enzyme elevations in patients with ACS have not
been well-studied.8,9 Because almost one-fourth of
patients with ACS undergo PCI during their initial
hospitalization, and non-fatal ischaemic events are often
incorporated into definitions for clinical trial end-points,
cardiac enzyme elevations after PCI could significantly
influence individual outcomes and the results of trials
that include patients with ACS.10–13
The Global Use of Strategies To Open occluded cor-
onary arteries in acute coronary syndromes (GUSTO-IIb),
Platelet glycoprotein in Unstable angina Receptor Sup-
pression Using Integrilin Therapy (PURSUIT), Platelet IIb/
IIIa Antagonism for the Reduction of Acute coronary
syndrome events in a Global Organization Network
(PARAGON-A), and PARAGON-B trials evaluated new
antithrombotic and antiplatelet therapies for patients
with non-ST segment elevation (NSTE) ACS. We evaluated
patients from these trials who underwent PCI during
the initial hospitalization to assess the impact of peri-
procedural CK-MB elevations on clinical outcomes.
Methods
Study population
The enrolment criteria for these trials were similar across
trials.10–12,14 Patients with NSTE ACS were enrolled if they had
ischaemic chest pain within 12–24 h before presentation with
electrocardiographic (ECG) signs of ischaemia or elevated serum
cardiac markers, including troponin I or T or CK-MB. The sub-
group of patients in the GUSTO-IIb trial with persistent ST-
segment elevation was not evaluated. The institutional review
committees of all participating hospitals approved the study
protocols, and all subjects gave informed consent.
Randomization and treatment
In GUSTO-IIb, patients were randomized to receive intravenous
unfractionated heparin or recombinant hirudin for 3–5 days.10 In
PURSUIT, patients were randomized in a double-blind fashion to
receive placebo or one of two doses of the platelet glycoprotein
IIb/IIIa inhibitor eptifibatide for 3–4 days.11 In PARAGON-A,
patients were randomized in a 2×2 factorial design to receive
low-dose lamifiban (a glycoprotein IIb/IIIa inhibitor), high-dose
lamifiban with intravenous heparin, or placebo with intravenous
heparin for 3–5 days.12 In PARAGON-B, patients were random-
ized to receive lamifiban or placebo for 3–5 days, and study drug
was adjusted for renal function.14
Concomitant treatment
Aspirin (80–325 mg daily) was recommended for all trial
patients. Heparin was recommended for all patients in PURSUIT
and PARAGON-B but was not required.11,14 Heparin use was
determined by randomized treatment assignment in GUSTO-IIb
and PARAGON-A. Other medications were given at the discretion
of the treating physicians. Decisions about coronary angiogra-
phy, PCI, and bypass surgery were not protocol-mandated and
were made by the treating physician. Routine surveillance of
CK-MB levels was strongly recommended at enrolment, after
recurrent ischaemic events, and after revascularization (PCI or
bypass surgery) but was not mandated by the study protocols.
CK-MB levels were analysed locally at participating sites and in
a central core laboratory in a portion of patients from
PARAGON-B.
Patient selection
The study group included all patients with NSTE ACS from the
respective trials who underwent PCI during the initial hospital-
ization. Patients who did not have CK-MB levels measured <24 h
after PCI and those who had a measured total CK or CK-MB level
>1 times the upper limit of normal (×ULN) in the 24 h before PCI
were excluded from the primary analysis. Patients with
measured CK-MB levels had ≥1 CK-MB level recorded on the case
report form within 24 h after PCI.
End-points
The primary end-point of this analysis was all-cause mortality
through 6 months, the longest common follow-up period among
the trials. Additional in-hospital outcomes evaluated after PCI
included congestive heart failure (new onset of dyspnoea with
evidence of heart failure on physical examination), shock (per-
sistent hypotension, diminished cardiac output, and evidence of
end-organ hypoperfusion), and arrhythmias (ventricular fibril-
lation or tachycardia, atrial fibrillation or flutter, or advanced
atrioventricular block). The incidence of (re)infarction after PCI
was not evaluated, because repeat infarctions were not consist-
ently collected and recorded among the trials when patients had
multiple recurrent ischaemic events. Events occurring before
PCI were not evaluated.
Comparison groups
Patients with ≥1 CK-MB level measured <24 h after PCI were
stratified into categories by peak CK-MB ratios of 0–1, 1–3, 3–5,
5–10, and >10×ULN for statistical comparisons. The absolute
peak CK-MB values for each patient were transformed into peak
CK-MB ratios with the following formula: peak CK-MB
ratio=actual peak CK-MB value divided by the ULN for CK-MB
from the local institution, according to expert recommen-
dations.1,15 The clinical characteristics and outcomes of patients
excluded from the primary analysis were not directly compared
but were recorded to describe differences between excluded
patients and the primary analysis group. Baseline characteristics
of patients undergoing PCI from the different trials also were
compared to assess differences across the populations.
Statistical analysis
Baseline, angiographic, and procedural characteristics are pre-
sented as numbers and percentages for categorical variables and
as medians with 25th and 75th percentiles for continuous
variables. Likelihood ratio chi-square, Mantel–Haenszel chi-
square, Kruskal–Wallis, and Wilcoxon rank-sum tests were used
to compare baseline categorical and continuous variables,
respectively, among the comparison groups.
Kaplan–Meier event rates through 6 months were determined
by peak CK-MB categories. Log-rank statistics were used to
compare unadjusted clinical event rates among patients in
the different peak CK-MB categories. We also determined the
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unadjusted continuous relationship between peak CK-MB levels
after PCI and 6-month mortality after transforming continuous
peak CK-MB levels into splines.16
A multivariable regression model was developed from the
PURSUIT database that reliably predicts 30-day mortality among
patients with NSTE ACS from eight baseline clinical characteris-
tics (age, systolic blood pressure, heart rate, previous angina,
male sex, ST-segment depression, enrolment infarction, and
signs of congestive heart failure) that were shown to be the
strongest predictors of mortality in a larger, expanded regres-
sion model.17 The variable ‘signs of congestive heart failure’
from the model was denoted as physical examination findings
consistent with congestive heart failure upon hospital presen-
tation. Variables added to the established model for this analysis
included angiographic characteristics (two- and three-vessel
coronary disease), unsuccessful PCI (stenosis >50% or Throm-
bolysis In Myocardial Infarction [TIMI] grade <3 flow after PCI),
experimental treatment (hirudin, eptifibatide, or lamifiban) as
a dichotomous variable that denotes experimental treatment
versus non-experimental treatment, time to PCI, and peak
CK-MB ratio as a continuous variable (per one unit increase
above ULN). Left ventricular ejection fraction could not be
included in the multivariable model because it was not recorded
on data-collection forms in 2470 of 5468 patients analysed
(45.2%). The continuous form of peak CK-MB levels was trans-
formed into splines for incorporation into the model.16 Testing
for linearity using the independent splines yielded non-
significant results, hence the linearity assumption was satisfied
and peak CK-MB ratio as a continuous variable was incorporated
into the model in its true state with no transformations.
Based on Cox proportional-hazards modelling, Wald chi-
square analyses were used to determine significant predictors of
6-month mortality and to test the statistical significance of the
relationship of the continuous peak CK-MB ratio variable to
6-month mortality. Linear hypothesis testing was used to evalu-
ate the relation of peak CK-MB ratio categories with 6-month
mortality in a separately fitted version of the regression model
rather than peak CK-MB ratio as a continuous variable. Inter-
actions between the different categories of peak CK-MB ratios
and time to death were tested to verify the proportional hazards
assumption. Based upon non-significant P-values for these inter-
actions, the assumption was considered to be valid.
An interaction term between experimental treatment and
peak CK-MB ratio was incorporated into the regression model
to evaluate the impact of the assigned treatments (hirudin,
eptifibatide, or lamifiban) on the predictive capabilities of peak
CK-MB ratios. Experimental treatment was considered to be
a dichotomous variable that denotes experimental treatment
versus non-experimental treatment. Trial enrolment was not
included in the final regression model because this variable
depends linearly on experimental treatment, but a separately
fitted version of the model that did not include experimental
treatment showed no interaction between trial enrolment (using
GUSTO-IIb as the reference) and peak CK-MB ratio categories
(using the group with peak CK-MB ratios 0–1×ULN as the refer-
ence) with linear hypothesis testing (Wald chi square, 0.86,
df=3, P=0.83).
Results
Patients
A total of 26,465 patients with NSTE ACS were enrolled in
the four trials. About one-fourth of the patients (23.3%)
underwent PCI during the initial hospitalization (n=6164).
CK or CK-MB levels <24 h before PCI were elevated in 696
patients, who were excluded. The primary analysis co-
hort included 2384 of the remaining 5468 patients (43.6%)
who had ≥1 CK-MB level measured <24 h after PCI. A total
of 3084 patients (56.4%) without CK-MB elevation before
PCI did not have CK-MB levels measured after PCI. The
breakdown of patients with measured CK-MB levels after
PCI from each trial included: 390 of 1594 patients from
GUSTO-IIb (24.5%), 1280 of 2226 patients from PURSUIT
(57.5%), 63 of 334 patients from PARAGON-A (18.9%), and
651 of 1314 patients from PARAGON-B (49.5%).
Clinical, treatment, and procedural
characteristics
Clinical characteristics differed significantly across the
trials among patients undergoing PCI (after excluding
those with pre-procedural CK-MB elevations) (Table 1). In
the combined dataset, the incidence of hypercholestero-
lemia, prior PCI, previous angina, and T-wave inversions
Table 1 Baseline clinical characteristics by trial enrolment for all patients undergoing PCI
GUSTO-IIb
(n=1594)
PURSUIT
(n=2226)
PARAGON-A
(n=334)
PARAGON-B
(n=1314)
P
valuea
Age (years) 62 (54, 70) 62 (53, 69) 64 (55, 70) 61 (52, 70) 0·07
Male sex 71.0% 69·3% 72·2% 72·1% 0·30
Heart rate (bpm) 72 (63, 81) 70 (61, 80) 74 (64, 84) 73 (64, 85) <0.001
Systolic BP (mmHg) 137 (120, 150) 130 (115, 142) 144 (130, 160) 140 (125, 160) <0.001
Diabetes 18.6% 20.2% 13.2% 21.7% 0.002
Enrolment infarction 47.7% 37.7% 28.0% 40.9% <0.001
Prior infarction 26.9% 29.1% 30.5% 28.2% 0.37
Prior PCI 17.4% 20.3% 17.1% 21.9% 0.01
Prior bypass surgery 12.8% 14.7% 12.6% 15.4% 0.15
Prior CHF 3.3% 6.7% 3.9% 8.1% <0.001
ECG findings
ST depression 54.0% 30.6% 60.7% 42.9% <0.001
Transient ST elevation 17.0% 10.6% 22.8% 17.3% <0.001
T-wave inversion 53.2% 53.6% 56.3% 45.9% <0.001
aAcross trials.BP=blood pressure; PCI=percutaneous coronary intervention; CHF=congestive heart failure; ECG=electrocardiographic.
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on the presenting ECG decreased with higher peak CK-MB
ratios (Table 2). The incidence of enrolment MI, ST-
segment depression, and transient ST-segment elevation
increased with higher peak CK-MB categories. In-hospital
and discharge medication use was similar across the peak
CK-MB categories except for greater use of angiotensin-
converting enzyme (ACE) inhibitors and in-hospital anti-
arrhythmic medications in patients with higher peak
CK-MB ratios (Table 3)
Angiographic findings showed that patients with
higher peak CK-MB ratios more commonly had multivessel
coronary disease, impaired left ventricular systolic func-
tion, and lower rates of procedural success (Table 4). The
median time to PCI was shorter in patients with higher
peak CK-MB ratios.
Unadjusted clinical outcomes
The unadjusted frequencies of death, congestive heart
failure, cardiogenic shock, and arrhythmias during the
initial hospitalization were increased with higher peak
CK-MB ratio categories, but the highest in-hospital mor-
tality rate was seen in the group with peak CK-MB rations
Table 2 Baseline clinical characteristics by peak creatine kinase (CK)-MB ratio category
Not measured >1×ULN, 24 h
Peak CK-MB elevation after PCI, ×ULN
after PCI
(n=3084)
Pre-PCI
(n=696)
0–1
(n=1335)
1–3 (n=508) 3–5 (n=144) 5–10
(n=170)
>10 (n=227) Pa
Age (years) 62 (53, 70) 59 (51, 69) 61 (52, 68) 62 (53, 69) 62 (54, 69) 62 (53, 70) 62 (50, 72) 0.46
Male sex 71.5% 73.6% 67.9% 69.7% 70.1% 72.9% 70.9% 0.46
Heart rate (per min) 72 (62, 80) 71 (62, 82) 71 (62, 82) 70 (62, 80) 73 (64, 82) 70 (64, 80) 70 (64, 82) 0.85
Systolic BP (mmHg) 136 (120,
150)
130 (115,
148)
132 (120,
150)
130 (120,
150)
130 (118,
146)
134 (115,
150)
130 (116,
148)
0.05
Hypertension 50.1% 50.9% 57.4% 51. 0% 58.3% 52.9% 49.3% 0.04
Diabetes 18.7% 18.7% 21.9% 18.3% 22.9% 21.8% 20.7% 0.53
Current smoking 37.0% 36.7% 32.5% 37.5% 33.9% 32.9% 36.3% 0.36
Hypercholesterolaemia 48.0% 47.0% 51.4% 48.5% 50.4% 47.1% 37.2% 0.003
Enrolment infarction 39.6% 84.0% 31.1% 47.3% 59.0% 57.5% 72.8% <0.001
Prior infarction 28.1% 26.7% 29.4% 30.1% 25.2% 24.3% 23.9% 0.22
Prior PCI 18.3% 19.1% 22.2% 22.3% 20.8% 29.2% 15.9% 0.04
Prior bypass surgery 13.1% 13.4% 16.0% 15.4% 18.1% 17.1% 12.8% 0.67
Prior CHF 5.5% 6.2% 6.4% 6.5% 4.2% 6.5% 7.9% 0.72
Previous angina 74.8% 65.8% 83.3% 83.1% 76.4% 77.7% 70.0% <0.001
ECG findings
ST depression 45.8% 36.9% 33.0% 39.2% 37.1% 40.6% 46.5% 0.001
Transient ST elevation 15.2% 17.3% 12.5% 12.9% 15.6% 21.9% 21.0% <0.001
T-wave inversion 51.9% 46.0% 54.7% 50.7% 48.6% 41.6 44.3% <0.001
aAcross peak CK-MB ratio categories of 0–1, 1–3, 3–5, 5–10, and >10×ULN. ULN=upper limit of normal; BP=blood pressure; PCI=percutaneous coronary
intervention; CHF=congestive heart failure; ECG=electrocardiographic.
Table 3 Medication use by peak creatine kinase (CK)-MB ratio category
Peak CK-MB Elevation After PCI, ×ULN
0–1 (n=1335) 1–3 (n=508) 3–5 (n=144) 5–10 (n=170) >10 (n=227) Pa
In-hospital
Aspirin 68.6% 72.6% 70.8% 71.8% 74.0% 0.30
Beta-blockers 52.7% 58.3% 56.3% 55.3% 58.1% 0.20
ACE-inhibitors 18.2% 23.4% 22.9% 27.1% 30.0% <0.001
Anti-arrhythmics 4.2% 5.3% 7.6% 10.0% 14.1% <0.001
Lipid lowering agents 21.4% 18.5% 19.4% 21.8% 18.9% 0.64
Discharge
Aspirin 66.0% 68.0% 64.6% 68.2% 67.3% 0.89
Beta-blockers 44.7% 48.2% 43.1% 45.9% 46.3% 0.69
ACE-inhibitors 16.0% 20.1% 19.4% 22.4% 26.9% 0.001
Anti-arrhythmics 1.8% 1.2% 2.1% 4.1% 2.2% 0.19
Lipid lowering agents 23.0% 21.5% 22.9% 24.7% 18.1% 0.47
aAcross peak CK-MB ratio categories of 0–1, 1–3, 3–5, 5–10, and >10×ULN. PCI=percutaneous coronary intervention; ULN=upper limit of normal;
ACE=angiotensin converting enzyme.
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3–5×ULN (Table 5). Cumulative mortality rates through
30 days and 6 months were also increased with higher
peak CK-MB ratio categories and the highest 6-month
mortality rate seen in the group with peak CK-MB ratios
>10×ULN. While there was a marginally significant differ-
ence in 6-month mortality rates among the groups with
peak CK-MB ratios of 3–5, 5–10, and >10×ULN (three-way
P-value=0.0498), Kaplan–Meier mortality curves showed
early separation between these peak CK-MB categories
and the lower peak CK-MB categories (Table 5 and Fig. 1).
The continuous relationship of peak CK-MB ratio with
6-month mortality demonstrated that higher peak CK-MB
ratios were associated with a greater risk of 6-month
mortality compared with lower levels of CK-MB elevation
(Fig. 2).
Multivariable predictors of mortality
After adjustment for clinical, angiographic, and treat-
ment characteristics, age, three-vessel coronary disease,
unsuccessful PCI, peak CK-MB ratio as a continuous vari-
able, and previous angina were significant predictors of
6-month mortality (Table 6). The interaction term be-
tween experimental treatment versus placebo and peak
Table 4 Angiographic and procedural characteristics by peak creatine kinase (CK)-MB ratio category
Not measured >1×ULN, 24 h
Peak CK-MB elevation after PCI, ×ULN
after PCI
(n=3084)
Pre-PCI
(n=696)
0–1
(n=1335)
1–3
(n=508)
3–5
(n=144)
5–10
(n=170)
>10
(n=227)
Pa
No. diseased vessels 0.005
One 52.0% 47.7% 51.1% 47.5% 46.6% 45.9% 45.1%
Two 30.4% 31.8% 30.2% 32.4% 27.8% 28.3% 30.9%
Three 16.9% 20.1% 18.3% 20.1% 25.6% 25.2% 24.0%
LV systolic functionb <0.001
Normal, EF >55% 56.0% 37.4% 57.2% 47.9% 52.3% 55.5% 30.8%
Mild, EF 40–55% 31.8% 44.4% 31.3% 33.5% 36.1% 29.7% 44.6%
Moderate, EF 30–40% 8.2% 13.8% 8.4% 11.3% 9.3% 9.9% 17.7%
Severe, EF <30% 4.0% 4.4% 3.1% 7.4% 2.3% 5.0% 6.9%
Median time to PCI, h 119 (69, 211) 29 (20, 29) 70 (26, 138) 57 (13, 120) 28 (4, 94) 20 (3, 91) 7 (2, 69) <0.001
Devices usedc
Angioplasty only 57.6% 38.4% 42.0% 42.1% 43.1% 48.8% 48.5% 0.22
Stent 37.9% 59.2% 55.8% 54.1% 50.7% 50.0% 48.0% 0.15
Other deviced 4.4% 5.0% 5.6% 5.3% 6.9% 5.3% 6.6% 0.91
Procedural successe 65.0% 95.0% 88.6% 81.7% 76.8% 76.7% 64.9% <0.001
aAcross peak CK-MB ratio categories of 0–1, 1–3, 3–5, 5–10, and >10×ULN.
bEjection fraction recorded in 2470 of 5468 patients.
cNot mutually exclusive.
dIncludes atherectomy, rotablation, laser angioplasty, or extraction catheters. Does not include distal protection devices.
ePostintervention TIMI grade 3 flow or lesion stenosis <50%. PCI=percutaneous coronary intervention; ULN=upper limit of normal; LV=left ventricular;
EF=ejection fraction.
Table 5 Unadjusted clinical outcomes by peak creatine kinase (CK)-MB ratio category
Not measured >1×ULN, 24 h
Peak CK-MB elevation after PCI, ×ULN
after PCI
(n=3084)
Pre-PCI
(n=696)
0–1
(n=1335)
1–3
(n=508)
3–5
(n=144)
5–10
(n=170)
>10
(n=227)
Pa
In-hospital
Mortality 0.5% 0.9% 0.3% 1.0% 4.2% 2.4% 2.6% 0.001
Heart failure 0.4% 1.0% 0.1% 0.8% 3.4% 4.1% 6.1% <0.001
Cardiogenic shock 0.2% 0.4% 0.1% 1.3% 2.0% 2.3% 2.6% 0.004
Arrhythmiasb 1.0% 3.3% 0.8% 1.9% 6.9% 4.1% 7.9% <0.001
30 Days
Mortality 0.8% 1.4% 0.7% 1.2% 4.2% 2.9% 3.1% <0.001
6 Months
Mortality 1.3% 2.6% 2.1% 2.4% 4.9% 4.1% 5.7% 0.005
Repeat intervention 24.0% 8.3% 10.4% 15.6% 20.1% 12.9% 23.8% <0.001
Bypass surgery 2.3% 5.6% 3.5% 6.9% 4.9% 8.8% 5.7% 0.02
aAcross peak CK-MB ratio categories of 0–1, 1–3, 3–5, 5–10, and >10×ULN.
bIncludes ventricular tachycardia or fibrillation, atrial fibrillation or flutter, and atrioventricular block. PCI=percutaneous coronary intervention;
ULN=upper limit of normal.
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CK-MB ratio was not significant (risk ratio [RR], 1.02; 95%
confidence interval [CI], 0.94–1.12; P=0.58) and was
therefore dropped from the model.
When peak CK-MB ratios were analysed by distinct
categories in the regression model, linear hypothesis
testing revealed a non-significant trend for an association
for an increased risk of 6-month mortality with higher
peak CK-MB categories (Wald chi square, 8.63; df=4,
P=0.07). The adjusted risk of 6-month mortality was not
increased significantly with peak CK-MB ratios of
1–3×ULN (RR, 1.15; 95% CI, 0.53–2.48; P=0.72) compared
with the reference group of peak CK-MB ratios of
0–1×ULN, but was increased to similar extents with peak
CK-MB ratios of 3–5×ULN (RR, 2.82; 95% CI, 1.11–7.16;
P=0.03), 5–10×ULN (RR, 2.64; 95% CI, 1.04–6.72; P=0.04),
and >10×ULN (RR, 2.13; 95% CI, 0.91–4.96; P=0.08).
Discussion
We have shown an association between higher levels of
peak CK-MB elevation after PCI and an increased risk of
adverse outcomes in patients with NSTE ACS. This study
provides unique insight into the relationship between
periprocedural myocardial necrosis and adverse clinical
outcomes, given that peak CK-MB levels after PCI were
analysed both continuously and categorically in a high-
risk population that was previously not well-studied.
Furthermore, the prognostic implications of peri-
procedural CK-MB elevations were confirmed with an
expanded version of a validated multivariable regression
model that also adjusted for angiographic and procedural
factors known to be significant predictors of mortality.
Therefore, these results further highlight the adverse
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prognostic implications of periprocedural myocardial
necrosis and underscore the importance of routine
surveillance of CK-MB levels after PCI.
Despite the demonstrated association between
periprocedural myocardial necrosis and mortality, the
pathophysiological mechanisms underlying cardiac en-
zyme elevation and subsequent adverse clinical out-
comes remain controversial. Periprocedural necrosis is
often caused by procedural complications such as side-
branch occlusion, abrupt closure, or coronary dissec-
tion.6,18 Our results show a correlation between lower
rates of procedural success and higher peak CK-MB levels
after PCI, but embolization of atherosclerotic and throm-
botic material to the distal coronary circulation is
thought to occur commonly during PCI, even without
obvious procedural complications.7 Contrast-enhanced
magnetic resonance imaging has shown that patients with
minor CK-MB elevations after uncomplicated PCI have
regions of hyper-enhancement within the perfusion
territory of the target vessel, corresponding to small
infarctions that may be caused by embolization of small
amounts of thrombus not seen on angiography.19 How-
ever, greater atherosclerotic plaque burden has been
shown to be associated with an increased likelihood of
periprocedural CK-MB release in this analysis and other
studies, so cardiac enzyme elevations after PCI may also
be a marker of high-risk features in patients without an
obvious MI.20,21 Thus, although a definite cause-and-
effect relation between periprocedural myocardial
necrosis and later adverse outcomes has not been shown,
CK-MB elevations after PCI have clear adverse prognostic
implications for risk stratification of patients with NSTE
ACS undergoing PCI.
Although the degree of periprocedural myocardial
necrosis appears to be related quantitatively to the risk
of adverse outcomes, the classification and definition of
periprocedural MI has been extensively debated.1,2,4,5,15
We evaluated periprocedural CK-MB levels in a continu-
ous fashion and showed an association between the risk
of mortality and higher levels of CK-MB elevation (above
a threshold with low peak CK-MB ratios). Furthermore,
the association between peak CK-MB levels and mortality
was not as strong when peak CK-MB ratios were analysed
as distinct categories in the regression model, perhaps
due to the relatively small numbers of patients in each
category. Recent retrospective studies have suggested
that only major categories of CK-MB elevations (>5–
10×ULN) delineate an independent contribution to mor-
tality risk after elective PCI, but patients with lower
levels of CK-MB elevations did have a slightly higher risk
of mortality in these studies and the risk associated with
CK-MB levels was not evaluated in a continuous
fashion.22–24 However, consensus statements suggest
that any degree of CK-MB elevation after PCI is associated
with adverse prognostic implications.1,15 Therefore,
CK-MB elevation after PCI appears to be associated with a
continuum of risk, but further analyses are needed to
clearly define a clinically useful threshold of CK-MB
elevation for risk stratification of patients undergoing
PCI.
The definition of MI has evolved with the introduc-
tion of new cardiac markers, such as the troponins I and
T, but distinctions between spontaneous and peripro-
cedural myocardial damage in patients with ACS remain
poorly characterized.25 The degree of spontaneous
CK-MB elevation in patients with ACS who do not
undergo revascularization correlates with an increased
risk of adverse outcomes, and infarctions that occur
after hospital admission are associated with an even
greater risk of mortality than are infarctions present at
admission.26,27 In this analysis, patients with elevated
CK-MB levels after PCI had a higher risk of mortality
compared with patients with elevated CK or CK-MB
levels <24 h before PCI, indicating that periprocedural
myocardial necrosis may confer a worse prognosis than
spontaneous necrosis from the presenting ischaemic
event.27 Furthermore, periprocedural CK-MB elevation
may reflect greater cumulative myocardial damage in
Table 6 Multivariable predictors of 6-month mortality
Variable Wald chi square Risk ratio (95% confidence interval) P value
Agea 10.99 1.06 (1.02–1.09) <0.001
Three-vessel coronary disease 10.43 3.36 (1.61–7.02) 0.001
Unsuccessful procedureb 6.47 2.46 (1.23–4.93) 0.011
Peak creatine kinase (CK)-MB ratioa 5.66 1.06 (1.01–1.11) 0.017
Previous angina 3.98 7.98 (1.04–61.35) 0.05
Male sex 2.23 1.47 (0.89–2.44) 0.14
ST-segment depression 1.58 0.64 (0.32–1.28) 0.21
Heart ratea 1.27 1.01 (0.99–1.03) 0.26
Systolic blood pressurea 1.26 0.99 (0.98–1.00) 0.26
Signs of congestive heart failure 0.83 1.51 (0.62–3.67) 0.36
Experimental treatmentc 0.57 1.28 (0.68–2.40) 0.45
Enrolment infarction 0.48 0.79 (0.40–1.56) 0.49
Time to percutaneous coronary intervention 0.12 1.00 (0.99–1.01) 0.73
Two-vessel coronary disease 0.05 0.90 (0.37–2.20) 0.82
aContinuous variables.
bStenosis >50% or TIMI grade <3 flow after the procedure.
cHirudin, eptifibatide, or lamifiban.Overall model chi square, 64.12 with 14 degrees of freedom.
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ACS patients with spontaneous myocardial necrosis and
may partly explain the adverse consequences of post-
admission infarctions.27 Although larger, prospective
studies are needed to determine the ideal thresholds
and markers for the classification of spontaneous and
periprocedural infarctions in patients with ACS, the
long-term risks of myocardial necrosis appear to be
similar irrespective of the mechanism of ischaemic
insult.2,3,7,15,27
Although this study represents the largest evaluation
of periprocedural CK-MB elevations in patients with
ACS, it has several limitations. First, because CK-MB
sampling after PCI was not mandated by the study
protocols, the sample size was limited and a selection
bias was present, in that CK-MB levels may have been
measured only in higher-risk patients. However, other
contemporary ACS databases do not include routine
cardiac enzyme data in all patients after PCI, so this
analysis represents the largest accumulation of peripro-
cedural CK-MB data in patients with ACS. We also
presented results for patients who did not have CK-MB
levels measured after PCI in an attempt to account for
this selection bias. Second, patients with myocardial
necrosis before PCI may have been misidentified as
having periprocedural infarctions. Although we ex-
cluded patients with elevated CK or CK-MB levels <24 h
before PCI to limit confounding from spontaneous
infarctions, the median time to PCI was progressively
shorter with higher peak CK-MB ratios. This suggests
that patients with large CK-MB elevations after PCI may
have had spontaneous infarctions at arrival that were
not identified before PCI was performed. Third, we
could not assess the impact of symptoms of ischaemia,
ECG changes, or detailed angiographic complications
on the unfavourable prognosis associated with peri-
procedural CK-MB elevations, because these data were
not systematically collected. Fourth, distal protec-
tion devices have been shown to limit embolization of
atherosclerotic and thrombotic debris to the coronary
microcirculation and reduce the incidence of peri-
procedural infarctions.28 However, distal protection
devices were not clinically available during the
time periods of these studies (1994–1999), so we could
not assess the impact of these devices on our
findings.10–12,14 Fifth, we could not adjust for ejection
fraction in the regression model because it was not
recorded on the case report form in almost half of the
patients. However, the regression model did include
the variable ‘signs of congestive heart failure’, which
represented the clinical manifestations of left ventricu-
lar dysfunction. Sixth, differences among the trial
populations may have influenced the results, but the
inclusion criteria of the trials were similar and there
was no interaction between trial enrolment and peak
CK-MB ratio in the regression model. Finally, glycopro-
tein IIb/IIIa inhibitors reduce periprocedural CK-MB
elevations and could therefore have limited CK-MB
release after PCI, but there was no interaction
between experimental treatment and peak CK-MB ratio
in the regression model to indicate that such treatment
affected the findings.
Conclusions
In summary, periprocedural CK-MB elevation was inde-
pendently associated with an increased risk of mortality
and other early adverse outcomes in patients with
NSTE-ACS, but a definite cause and effect relationship
was not established. However, these results suggest that
risk stratification of ACS patients should include routine
surveillance of CK-MB levels after PCI to assess an indi-
vidual patient's risk of adverse outcomes and that
independent adjudication of suspected periprocedural
ischaemic events should be incorporated into end-point
definitions for clinical trials that include ACS patients.13
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